RecruitingNCT06482957
Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan
CAUSAL: Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan
Sponsor
Vanderbilt-Ingram Cancer Center
Enrollment
2,100 participants
Start Date
Apr 1, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
This study evaluates the impact that a sarcoma diagnosis and treatment have had on patients over time.
Eligibility
Inclusion Criteria4
- Patients at any age with a history of sarcoma, with or without evidence of a persistent disease
- For pediatric patients
- Parent/primary caregiver of patient
- Sibling of patient aged 8 years or older
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERSurveys
Complete surveys
OTHERBlood Collection
Undergo blood collection
OTHERSaliva Collection
Undergo salvia collection
OTHERUrine Collection
Undergo urine collection
OTHERStool Collection
Undergo stool collection
OTHERTissue collection
Undergo tissue collection
OTHERPhysical Activity Monitoring
FitBit will be worn to track physical activity
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06482957
Related Trials
A Checklist (Advanced Care Planning) for The Assessment of Mobility Needs in Patients With Sarcoma
NCT058351541 location
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069745 locations
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
NCT069752933 locations
DESTINY-PANTUMOUR04
NCT0712400015 locations
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
NCT023907521 location